Monoclonal antibody specific for the adhesion function domain of a phagocyte cell surface protein

• US 5,019,648 A
• Filed: 03/07/1988
• Issued: 05/28/1991
• Est. Priority Date: 07/06/1987
• Status: Expired due to Term

• Current Assignee: Dana-Farber Cancer Institute
• Original Assignee: Dana-Farber Cancer Institute
• Inventors: Griffin, James D., Schlossman, Stuart F.
• Primary Examiner(s): Kepplinger, Esther L.
• Assistant Examiner(s): Kushan, Jeff
• Application Number:
  US07/165,024
• Time in Patent Office: 1,177 Days
• Field of Search: 435/240.27, 435/68, 435/7, 435/172.2, 530/387, 530/809, 436/548, 935/100, 935/104, 935/107, 935/110, 424/85.8
• US Class Current: 530/388.7
• CPC Class Codes: C07K 16/2845 against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
• CPC Class Codes: Y10S 530/828 Cancer

Abstract

A hybrid cell line is developed which produces a monoclonal antibody which binds to a unique antigenic site expressed on the surface of phagocytic cells. The monoclonal antibody binds to and activates a specific domain of the CD11b glycoprotein so as to inhibit adhesion dependent functions of the phagocytic cell, but it does not affect other phagocytic functions. This monoclonal antibody can be used as a reactant in an in vitro diagnostic immunoassay for detecting the unique antigenic site on the surface of normal human neutrophils.

Claims

1. A monoclonal antibody which binds specifically to the epitope defined by the MY904 antibody, wherein said binding inhibits only the adhesion-dependent functions of granulocytes and monocytes without binding the iC3b component of complement, and wherein the antibody does not bind human T and B lymphocytes, said MY904 antibody being the antibody produced by the hybridoma having ATCC accession number HB9510.

2. A hybridoma cell line which produces the antibody of claim 1.

3. The cell line of claim 2 wherein said monoclonal antibody binds specifically to granulocytes from peripheral blood samples of chronic granulocytic leukemia origin.

4. The cell line of claim 2 wherein the monoclonal antibody binds specifically to normal monocytes, normal granulocytes and normal bone marrow mononuclear cells and does not bind to normal erthrocytes and platelets.

6. The monoclonal antibody of claim 1 which binds specifically to normal monocytes, normal granulocytes and normal bone marrow mononuclear cells and does not bind to normal erythrocytes and platelets.

7. The monoclonal antibody of claim 1 which does not bind specifically to normal erythrocytes and platelets.

8. The monoclonal antibody of claim 1 produced by the hybrid cell line having all the identifying characteristics of the A.T.C.C. deposit No. HB 9510.

9. The monoclonal antibody of claim 1 which does not bind specifically to human T or B lymphocytes.

5. The cell line produced by a hydridoma technique having all the identifying characteristics of the sample on deposit with the American Type Culture Collection No. HB9510 producing monoclonal antibody MY904 that specifically binds to the adhesion-domain of the CD116/CD18 phagocyte surface protein.